The FDA has approved the widespread use of @Bristol Myers Squibb’s drug Reblozyl for treating anemia in adult patients with beta-thalassemia who require regular blood transfusions and suffer from low-to-intermediate-risk myelodysplastic syndromes. Reblozyl can now be used to treat chronic anemia at an earlier stage for a broader range of patients. This expansion of the patient group was based on positive results from the COMMANDS trial. Additionally, the label expansion of these drugs is expected to fuel growth for the company.

At OxyDial, we are happy to see companies like Bristol Myers expanding their efforts to help patients with blood disorders improve their health and the company’s success in drug discovery and approval.

Read more:

#Reblozyl #anemia #blooddisorders #FDAapproval #BristolMyers #myelodysplasticsyndromes #beta_thalassemia #chronicanemia #patientcare